(Anaveon) ANV600 is a potent, cis-signaling, IL-2Rβ/γ directed IL-2 which efficiently expands intratumoral stem-like CD8 T cells
PD-1 & strong tumor growth inhibition
Background
ANV600 is a novel PD-1 targeted, IL-2Rβ/γ directed IL-2
ANV600 consists of a proprietary PD-1 binding moiety and an IL-2Rβ/γ directed interleukin-2/anti-IL-2 fusion protein, thus targeting the cytokine to PD-1 expressing T cells. The IL-2 agonist arm of ANV600 includes an anti-IL-2 antibody with high affinity to the IL-2Rα binding domain of IL-2. The cytokine is directly fused to the light chain of the antibody through a peptide linker, allowing ANV600 to present IL-2 to the dimeric β/γ IL-2 receptor on CD8 PD-1+ T cells, while sterically excluding binding to the high affinity trimeric α/β/γ IL-2 receptor.
![](https://cdn.prod.website-files.com/655dd3c88278aa64954052d4/667c0c70dc808527274680fc_anaveon-poster-aacr2023-pd-1_img01.jpg)
In the tumor microenvironment, the pool of PD-1+ T cells is primarily composed of tumor antigen experienced cells. ANV600 potently and selectively proliferates tumor specific PD-1+ stem-like CD8 T cells and effector cells, and markedly reduces tumor growth in poorly immunogenic syngeneic mouse tumor models.
Ultimate predictive models
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our modelsScientific excellence
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in FranceCustomer-centric
Tailor-made approach to your needs
Strong emphasis on customer satisfactionCollaborative partner
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate